T ANTIGEN IN BREAST AND PANCREAS CARCINOMA DETECTION

T 抗原在乳腺癌和胰腺癌检测中的应用

• 批准号: 3165087
• 负责人: GEORG F SPRINGER
• 金额: $ 11.24万
• 依托单位: EVANSTON HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-04-01 至 1987-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3165087
• 关键词: adenocarcinoma; biopsy; breast neoplasm /cancer diagnosis; breast neoplasms; cellular immunity; delayed hypersensitivity; early diagnosis; human subject; human therapy evaluation; human tissue; humoral immunity; immunity; immunochemistry; immunotoxicity; lung neoplasms; mammography; migration inhibition factor; neoplasm /cancer chemotherapy; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; pancreas neoplasms; plaque assay; radioimmunoassay; tumor antigens

We plan to extend studies with our so far (greater than 350 patients) sensitive and specific immunoassays in the detection (including early) of breast-, lung-, and pancreas adeno carcinoma (CA), and other CAs. We use the human T -- anti-T system to measure cell-mediated (CMI) as well as humoral immune responses towards CA-associated T antigen. T antigen does not occur in reactive form in non-CA tissue. However, it is readily prepared by a multistep procedure and slight chemical degradation from healthy, outdated human red blood cells. Delayed-type skin hypersensitivity to erythrocyte-derived T antigen as well as humoral anti-T response to T, measured by a novel quantitative immunofluorescent assay using insolubilized T antigen (SPIA-T), had greater greater than 80 percent sensitivity and greater than 90 percent specificity in detection of adeno- and small cell CA; toward squamous cell CA only SPIA-T, which is readily performed quantitatively and repeatedly, had such sensitivity. We want to distinguish early CA from nonmalignant and borderline lesions, and monitor the effect of therapy on CA. We intend to establish a rapid, economic assay for diagnosis of and possibly screening for CA. We will focus on early detection and on monitoring for recurrences. We are developing 2 in vitro tests to measure CMI to T, to circumvent the inconveniences of the delayed-type hypersensitivity skin test. We will extend successful attempts by others and by us to relate density of T receptors on CA cells with aggressiveness, and also that of Tn receptors. Satisfactory (early) diagnosis of CA requires precise localization of minute CA in addition to detection. We plan to establish firmly our preliminary work with human [131I]- anti-T IgG to localize T-active TA3 mouse mammary adenoCA metastases by external scanning in a step towards pinpointing early human CA and metastases. Implications of our work may be far-reaching, as we and others have indications that we measure a dynamic interaction of the cancer patient's immune system with the T-specific structures of the tumor.

我们计划扩大迄今为止的研究（超过 350 名患者） 检测（包括早期）中敏感和特异的免疫分析 乳腺癌、肺癌和胰腺癌 (CA) 以及其他 CA。 我们使用 人类 T——抗 T 系统，用于测量细胞介导的 (CMI) 以及 针对 CA 相关 T 抗原的体液免疫反应。 T抗原确实 在非 CA 组织中不会以反应形式发生。 然而，它很容易 通过多步程序和轻微化学降解制备 健康的、过时的人类红细胞。 延迟型皮肤 对红细胞衍生的 T 抗原以及体液抗 T 过敏 通过新型定量免疫荧光测定法测量对 T 的反应 使用不溶性 T 抗原 (SPIA-T)，有超过 80% 检测腺病毒时灵敏度和特异性超过 90% 和小蜂窝 CA；仅针对鳞状细胞 CA 的 SPIA-T，很容易 定量地、反复地进行，具有这样的敏感性。 我们想要 区分早期 CA 与非恶性和交界性病变，并监测 治疗对 CA 的影响。 我们打算建立一个快速、经济的 用于诊断和可能筛查 CA 的测定。 我们将重点关注 及早发现并监测复发情况。 我们正在开发 2 体外测试测量 CMI 到 T，避免了不便 迟发型超敏反应皮试。 我们将成功延续 其他人和我们尝试将 CA 细胞上 T 受体的密度联系起来 具有攻击性，还有 Tn 受体。 满意（早期） CA的诊断除了需要精确定位微小的CA之外 检测。 我们计划与人类牢固地建立我们的前期工作 [131I]- 抗 T IgG 定位 T 活性 TA3 小鼠乳腺腺 CA 通过外部扫描确定转移，朝着精确定位早期人类迈出了一步 CA 和转移。 我们的工作的影响可能是深远的，因为我们和 其他人有迹象表明我们测量了癌症的动态相互作用 患者的免疫系统与肿瘤的 T 特异性结构有关。